HFS
RCUS icon

Hantz Financial Services’s Arcus Biosciences RCUS Stock Holding History

Hantz Financial Services’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61K Buy
1,990
+233
+13% +$5.76K ﹤0.01% 1588
2026
Q1 		$38K Buy
1,757
+153
+10% +$3.3K ﹤0.01% 1653
2025
Q4 		$38K Buy
1,604
+881
+122% +$18K ﹤0.01% 1545
2025
Q3 		$10K Buy
723
+440
+155% +$4.58K ﹤0.01% 1838
2025
Q2 		$2K Buy
283
+272
+2,473% +$2.32K ﹤0.01% 2016
2025
Q1 		$0 Buy
+11
New +$128 ﹤0.01% 1922

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Hantz Financial Services's RCUS Position: Q2 2026 in Review

Hantz Financial Services increased its Arcus Biosciences (RCUS) stake by 13% in Q2 2026, buying an estimated $5.76K and bringing the position to 1,990 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #1588.

Hantz Financial Services first reported a position in RCUS in Q1 2025 and has held it in 6 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Hantz Financial Services held 1,990 shares of Arcus Biosciences worth $61K as of Q2 2026.
  • Hantz Financial Services bought 233 Arcus Biosciences shares in Q2 2026, an estimated $5.76K.
  • Arcus Biosciences made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1588 holding.
  • Hantz Financial Services first reported a position in Arcus Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.